In our industry, partnering is a way of life. Not only does selectively partnering ensure that we have the resources to develop our products to their full potential, but it also brings access to new capabilities and talent from which our scientists and clinicians can gain new insights.

Our existing collaborations with Biogen Idec and Bristol-Myers Squibb are fantastic examples of how we can leverage alliances with leading pharmaceutical and biotechnology companies to increase our chances of successfully bringing new drugs to market. We also pride ourselves in exploring new ways to augment our existing pipeline of drugs through both strategic partnerships and in-licensing activities. And, finally, we have a number of existing licensing and other agreements with various companies.

Learn more about these key development collaborations:

Biogen Idec

Our collaboration agreement with Biogen Idec provides for the joint development, manufacture and commercialization of daclizumab in MS and indications other than transplant and respiratory diseases, and for shared development and commercialization of volociximab (M200) in all indications. This agreement requires each party to undertake extensive efforts in support of the collaboration and requires the performance of both parties to be successful. We currently split the costs of U.S. and European development activities and, if any of the products are commercialized, we will also split all operating profits with Biogen Idec.  We each hold co-promotion rights in the U.S. and Europe based upon our sales capabilities at the time.  Outside the U.S. and Europe, Biogen Idec will fund all incremental development and commercialization costs and pay a royalty to PDL on sales of collaboration products. We are eligible to receive development and commercialization milestones based on the further successful development of these antibodies.

Bristol-Myers Squibb

Under the terms of a 2008 co-development deal with Bristol-Myers Squibb, Facet Biotech is completing our ongoing elotuzumab phase 1 program , which consists of these studies, and will provide support for phase 2 studies.  The companies are sharing development costs (20% Facet Biotech; 80% Bristol-Myers).  If approved, the companies will share profits on sales of elotuzumab in the U.S. and Facet Biotech will receive royalties on net sales of elotuzumab outside the U.S.  Bristol-Myers also has an option to expand this collaboration to include PDL241, which is another anti-CS1 antibody.

Our Pipeline
R&D
Careers at Facet Biotech